Skip to content

Amneal Pharmaceuticals

US · AMRX #1854 by market cap Listed 1970
21.12 -0.27 -1.26%
Periodic snapshot; not a real-time feed. · 2026-11-20 20:02

Valuation each multiple against its own 5-year range

P/B ratio 14.02 Expensive vs history 91st percentile
5-year average -4.35 · #65 of 69 in Drug Manufacturers - Specialty & Generic
P/E ratio 53.45 Expensive vs history 69th percentile
5-year average 122.82 · forward 38.09 · #20 of 25 in Drug Manufacturers - Specialty & Generic
P/S ratio 2.33 Expensive vs history 100th percentile
5-year average 0.77 · forward 2.21 · #40 of 78 in Drug Manufacturers - Specialty & Generic

Vs. peers Drug Manufacturers - Specialty & Generic

Company Market cap P/E (TTM) P/B Div yield
Amneal Pharmaceuticals (AMRX) 7.36B 52.80 13.85 0.00%
Takeda Pharmaceutical (TAK) 69.76B 311.00 1.50 1.44%
Teva Pharmaceutical Industries (TEVA) 45.77B 91.23 5.74 0.00%
Haleon (HLN) 39.76B 19.14 1.85 2.09%
Zoetis (ZTS) 32.14B 13.34 9.73 2.64%
United Therapeutics (UTHR) 23.63B 20.94 3.76 0.00%

Other StockVane-tracked companies in the same industry.

Morningstar

★★★☆☆ Fair value19.99 Economic moatNarrow UncertaintyHigh

Trading 5.4% above Morningstar's fair value estimate.

Fair value

Amneal Pharmaceuticals Inc earns a 3-star quantitative star rating, indicating our belief that this share class is a balanced choice, but prudent investors should consider looking elsewhere. The stock currently trades at a 7% premium over our quantitative fair value estimate of $19.99 per share; however, this estimate should be taken with a pinch of salt due to its high uncertainty rating.

The company's valuation metrics decrease our fair value estimate. A company's valuation metrics provide insights into the market's expectations for its future growth and profitability. For example, the firm's book value yield of 7.6% sits in the bottom 10% compared with peers globally. The market value of this company's shares looks expensive relative to the book (accounting) value of equity, which contributes to our view that shares are expensive.

Alternatively, the firm's balance sheet is reassuring. Leverage can enable a company to invest in growth, potentially boosting shareholder value more than equity financing alone. The firm's EBITDA/interest coverage ratio of 2.9, a core component of leverage, lies in the bottom 30% globally. Although the firm's ability to cover interest payments with EBITDA is limited, shares could sharply rebound if economic circumstances change or recent investments reduce fears of default. Despite our unfavorable price/fair value ratio, this characteristic is a positive attribute.

In addition to the aforementioned drivers, our model considers momentum as part of its comprehensive analysis. This share class has outperformed the broader universe over the past year. This outperformance may signify a bull trap, in light of other detractors from our model.

Economic moat

The company's narrow economic moat rating suggests it should be able to maintain robust profitability for a decade or longer before competition erodes its advantage. In addition, the company's moderate financial health score is decent and doesn't seriously concern us with regard to financial distress.

By Quantitative Equity Report

Quote time 2026-11-20 20:02:15 · For reference only, not investment advice and not tailored to your situation.

Amneal Pharmaceuticals discussion 0 comments

Add a comment